Role of serotonin in Alzheimers disease: A new therapeutic target?

CNS Drugs

Volumn 25, Issue 9, 2011, Pages 765-781

  Geldenhuys, Werner J ^a   Van Der Schyf, Cornelis J ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Alzheimers disease; Serotonin; Serotonin receptor agonists; Serotonin receptor antagonists.

Indexed keywords

1 (1,4 BENZODIOXAN 5 YL) 4 (2 INDANYL)PIPERAZINE; 1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 (1 BUTYL 4 PIPERIDINYL) 1 PROPANONE; 1 BENZENESULFONYL 5 METHOXY N,N DIMETHYLTRYPTAMINE; 2 DIPROPYLAMINO 5 FLUORO 8 HYDROXYTETRALIN; 2 PIPERIDINOETHYL 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 2 (1 PIPERIDINYL)ETHYL ESTER; 4 AMINO 5 CHLORO N [(HEXAHYDRO 1H PYRROLIZIN 1 YL)METHYL] 2 METHOXYBENZAMIDE; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; DIMEBON; DONEPEZIL; GALANTAMINE; N (3,5 DICHLORO 2 METHOXYPHENYL) 4 METHOXY 3 (1 PIPERAZINYL)BENZENESULFONAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NOOTROPIC AGENT; PRUCALOPRIDE; RIVASTIGMINE; RO 046790; ROBALZOTAN; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; SEROTONIN RECEPTOR; SUVN 502; TACRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; CLINICAL FEATURE; COGNITION; DNA DAMAGE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME INHIBITION; HUMAN; INFLAMMATION; LEARNING; MEMORY; MICROTUBULE; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG SCREENING; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; RECEPTORS, SEROTONIN; SEROTONIN;

EID: 80052184853     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11590190-000000000-00000     Document Type: Review

References (110)

1. Geldenhuys WJ, Van der Schyf CJ. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease. Expert Rev Neurother 2009 Jul; 9 (7): 1073-85
2. Geldenhuys WJ, Van der Schyf CJ. Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease. Curr Top Med Chem 2008; 8 (12): 1035-48
3. Glennon RA, Siripurapu U, Roth BL, et al. The medicinal chemistry of 5-HT6 receptor ligands with a focus on arylsulfonyltryptamine analogs. Curr Top Med Chem 2010; 10 (5): 579-95
4. Holenz J, Pauwels PJ, Diaz JL, et al. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discov Today 2006 Apr; 11 (7-8): 283-99
5. King MV, Marsden CA, Fone KC. A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol Sci 2008 Sep; 29 (9): 482-92
6. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003 Aug; 60 (8): 1119-22
7. LaFerla FM. Pathways linking Abeta and tau pathologies. Biochem Soc Trans 2010 Aug; 38 (4): 993-5
8. Carter MD, Simms GA, Weaver DF. The development of new therapeutics for Alzheimer's disease. Clin Pharmacol Ther 2010 Oct; 88 (4): 475-86
9. Macmillan KS, Naidoo J, Liang J, et al. Development of proneurogenic, neuroprotective small molecules. J Am Chem Soc 2011; 133 (5): 1428-37
10. Robert SJ, Zugaza JL, Fischmeister R, et al. The human serotonin 5-HT4 receptor regulates secretion of nonamyloidogenic precursor protein. J Biol Chem 2001 Nov 30; 276 (48): 44881-8
11. Consolo S, Arnaboldi S, Giorgi S, et al. 5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex. Neuroreport 1994 Jun 2; 5 (10): 1230-2
12. Marcos B,Garcia-Alloza M, Gil-Bea FJ, et al. Involvement of an altered 5-HT-{6} receptor function in behavioral symptoms of Alzheimer's disease. J Alzheimers Dis 2008 May; 14 (1): 43-50 (Pubitemid 352039014)
13. Marcos B, Chuang TT, Gil-Bea FJ, et al. Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br J Pharmacol 2008 Oct; 155 (3): 434-40
14. Da Silva Costa V, Duchatelle P, Boulouard M, et al. Selective 5-HT6 receptor blockade improves spatial recognition memory and reverses age-related deficits in spatial recognition memory in the mouse. Neuropsychopharmacology 2009 Jan; 34 (2): 488-500
15. Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) 2004 Jun; 174 (1): 17-24 (Pubitemid 38925086)
16. Sumiyoshi T, Bubenikova-Valesova V, Horacek J, et al. Serotonin 1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics. Adv Ther 2008 Oct; 25 (10): 1037-56
17. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993 Mar 1; 90 (5): 1977-81 (Pubitemid 23069980)
18. Eto M, Watanabe K, Ishii K. A racial difference in apolipoprotein E allele frequencies between the Japanese and Caucasian populations. Clin Genet 1986 Nov; 30 (5): 422-7 (Pubitemid 17200192)
19. Martorana A, Esposito Z, Koch G. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? CNS Neurosci Ther 2010 Aug; 16 (4): 235-45
20. Bartus RT, Dean 3rd RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982 Jul 30; 217 (4558): 408-14
21. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2003 Sep; 2 (9): 539-47 (Pubitemid 36994993)
22. Nakajima Y, Nakajima S, Obata K, et al. Dissociated cell culture of cholinergic neurons from nucleus basalis of Meynert and other basal forebrain nuclei. Proc Natl Acad Sci USA 1985 Sep; 82 (18): 6325-9 (Pubitemid 16222877)
23. Wilkinson DG, Francis PT, Schwam E, et al. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004; 21 (7): 453-78 (Pubitemid 38736890)
24. Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer's disease: part II. Treatment. Am Fam Physician 2002 Jun 15; 65 (12): 2525-34 (Pubitemid 34664744)
25. Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer's disease: part I. Assessment. Am Fam Physician 2002 Jun 1; 65 (11): 2263-72 (Pubitemid 34603057)
26. Burns A, O'Brien J, Auriacombe S, et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006 Nov; 20 (6): 732-55 (Pubitemid 44622739)
27. Palmer AM. Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. Trends Pharmacol Sci 2011; 32 (3): 141-7
28. LaFerla FM, Green KN, Oddo S. Intracellular amyloidbeta in Alzheimer's disease. Nat Rev Neurosci 2007 Jul; 8 (7): 499-509
29. Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008 Nov 26; 60 (4): 534-42
30. Olsen RE, Marcin LR. Secretase inhibitors andmodulators for the treatment of Alzheimer's disease. Annu Rep Med Chem 2007; 42: 27-43
31. Pimplikar SW, Nixon RA, Robakis NK, et al. Amyloidindependent mechanisms in Alzheimer's disease pathogenesis. J Neurosci 2010; 30 (45): 14946-54
32. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 2004 Jul; 10 Suppl.: S2-9 (Pubitemid 38901861)
33. Jellinger KA. Alzheimer 100: highlights in the history of Alzheimer research. J Neural Transm 2006 Nov; 113 (11): 1603-23 (Pubitemid 44660049)
34. Lahiri DK, Farlow MR, Sambamurti K, et al. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 2003 Feb; 4 (2): 97-112 (Pubitemid 36553583)
35. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008 Aug; 14 (8): 837-42
36. Iqbal K, Liu F, Gong CX, et al. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 2010; 7 (8): 656-64
37. Iqbal K, Wang X, Blanchard J, et al. Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial. Biochem Soc Trans 2010 Aug; 38 (4): 962-6
38. Gentles RG, Hu S, Dubowchik GM. Recent advances in the discovery of GSK-3 inhibitors and a perspective on their utility for the treatment of Alzheimer's disease. Annu Rep Med Chem 2009; 44: 3-26
39. Auffret A, Mariani J, Rovira C. Age-related progressive synaptic dysfunction: the critical role of presenilin 1. Rev Neurosci 2010; 21 (4): 239-50
40. Nelson RB. Back to the plaque: emerging studies that refocus attention on the neuritic plaque in Alzheimer's disease. Annu Rep Med Chem 2010; 45: 315-27
41. Buhot MC, Martin S, Segu L. Role of serotonin in memory impairment. Ann Med 2000 Apr; 32 (3): 210-21 (Pubitemid 30237566)
42. Buhot MC, Malleret G, Segu L. Serotonin receptors and cognitive behaviour: an update. IDrugs 1999 May; 2 (5): 426-37 (Pubitemid 29230023)
43. Perez-Garcia G, Meneses A. Memory formation, amnesia, improved memory and reversed amnesia: 5-HT role. Behav Brain Res 2008 Dec 16; 195 (1): 17-29
44. Meltzer CC, Smith G, DeKosky ST, et al. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 1998 Jun; 18 (6): 407-30 (Pubitemid 28202350)
45. Leonard BE. Sub-types of serotonin receptors: biochemical changes and pharmacological consequences. Int Clin Psychopharmacol 1992; 7 (1): 13-21
46. Childers Jr WE, Robichaud AJ. Recent advances in selective serotonergic agents. Annu Rep Med Chem 2005; 40: 17-33 (Pubitemid 44262130)
47. Chalmers DT, Watson SJ. Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain: a combined in situ hybridisation/in vitro receptor autoradiographic study. Brain Res 1991 Oct 4; 561 (1): 51-60
48. Lacivita E, Leopoldo M, Berardi F, et al. 5-HT1A receptor, an old target for new therapeutic agents. Curr Top Med Chem 2008; 8 (12): 1024-34
49. Childers Jr WE, Havran LM, Asselin M, et al. The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists. JMed Chem 2010 May 27; 53 (10): 4066-84
50. Lai MK, Tsang SW, Francis PT, et al. Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res 2003 Jun 6; 974 (1-2): 82-7 (Pubitemid 36549222)
51. Millan MJ, Gobert A, Roux S, et al. The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis. J Pharmacol Exp Ther 2004 Oct; 311 (1): 190-203 (Pubitemid 39287799)
52. Vilaro MT, Cortes R, Gerald C, et al. Localization of 5-HT4 receptor mRNA in rat brain by in situ hybridization histochemistry. Brain Res Mol Brain Res 1996 Dec 31; 43 (1-2): 356-60 (Pubitemid 27042427)
53. Cho S, Hu Y. Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Exp Neurol 2007 Jan; 203 (1): 274-8 (Pubitemid 44821167)
54. Cachard-Chastel M, Lezoualc'h F, Dewachter I, et al. 5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice. Br J Pharmacol 2007 Apr; 150 (7): 883-92 (Pubitemid 46536635)
55. Manuel-Apolinar L, Rocha L, Pascoe D, et al. Modifications of 5-HT4 receptor expression in rat brain during memory consolidation. Brain Res 2005 Apr 25; 1042 (1): 73-81
56. Moser PC, Bergis OE, Jegham S, et al. SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J Pharmacol Exp Ther 2002 Aug; 302 (2): 731-41 (Pubitemid 34787242)
57. Letty S, Child R, Dumuis A, et al. 5-HT4 receptors improve social olfactory memory in the rat. Neuropharmacology 1997 Apr-May; 36 (4-5): 681-7 (Pubitemid 27272114)
58. Marchetti E, Chaillan FA, Dumuis A, et al. Modulation of memory processes and cellular excitability in the dentate gyrus of freely moving rats by a 5-HT4 receptors partial agonist, and an antagonist. Neuropharmacology 2004 Dec; 47 (7): 1021-35 (Pubitemid 39539226)
59. Marchetti E, Jacquet M, Jeltsch H, et al. Complete recovery of olfactory associative learning by activation of 5-HT4 receptors after dentate granule cell damage in rats. Neurobiol Learn Mem 2008 Jul; 90 (1): 185-91
60. Galeotti N, Ghelardini C, Bartolini A. Role of 5-HT4 receptors in the mouse passive avoidance test. J Pharmacol Exp Ther 1998 Sep; 286 (3): 1115-21 (Pubitemid 29135518)
61. Micale V, Leggio GM, Mazzola C, et al. Cognitive effects of SL65.0155, a serotonin 5-HT4 receptor partial agonist, in animal models of amnesia. Brain Res 2006 Nov 22; 1121 (1): 207-15 (Pubitemid 44708901)
62. Cachard-Chastel M, Devers S, Sicsic S, et al. Prucalopride and donepezil act synergistically to reverse scopolamineinduced memory deficit in C57Bl/6j mice. Behav Brain Res 2008 Mar 5; 187 (2): 455-61
63. Mohler EG, Shacham S, Noiman S, et al. VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux. Neuropharmacology 2007 Sep; 53 (4): 563-73 (Pubitemid 47284188)
64. Orsetti M, Dellarole A, Ferri S, et al. Acquisition, retention, and recall of memory after injection of RS67333, a 5-HT(4) receptor agonist, into the nucleus basalis magnocellularis of the rat. Learn Mem 2003 Sep-Oct; 10 (5): 420-6 (Pubitemid 37266687)
65. Lieben CK, Blokland A, Sik A, et al. The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuropsychopharmacology 2005 Dec; 30 (12): 2169-79 (Pubitemid 41643968)
66. Schaffhauser H, Mathiasen JR, Dicamillo A, et al. Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities. Biochem Pharmacol 2009 Oct 15; 78 (8): 1035-42
67. Matveeva IA. Action of dimebon on histamine receptors. Farmakol Toksikol 1983 Jul-Aug; 46 (4): 27-9 (Pubitemid 13038960)
68. Okun I, Tkachenko SE, Khvat A, et al. From anti-allergic to anti-Alzheimer's: molecular pharmacology of dimebon. Curr Alzheimer Res 2009 Mar; 7 (2): 97-112
69. Lermontova NN, Lukoyanov NV, Serkova TP, et al. Dimebon improves learning in animals with experimental Alzheimer's disease. Bull Exp Biol Med 2000 Jun; 129 (6): 544-6
70. Bezprozvanny I. The rise and fall of dimebon. Drug News Perspect 2010 Oct; 23 (8): 518-23
71. Bachurin S, Bukatina E, Lermontova N, et al. Antihistamine agent dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 2001 Jun; 939: 425-35 (Pubitemid 32620096)
72. Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebocontrolled study. Lancet 2008 Jul 19; 372 (9634): 207-15 (Pubitemid 351978110)
73. Lermontova NN, Redkozubov AE, Shevtsova EF, et al. Dimebon and tacrine inhibit neurotoxic action of betaamyloid in culture and block L-type Ca(2+) channels. Bull Exp Biol Med 2001 Nov; 132 (5): 1079-83 (Pubitemid 34295938)
74. Monsma Jr FJ, Shen Y, Ward RP, et al. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993 Mar; 43 (3): 320-7 (Pubitemid 23081986)
75. Ruat M, Traiffort E, Arrang JM, et al. A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem Biophys Res Commun 1993 May 28; 193 (1): 268-76 (Pubitemid 23199942)
76. Fone KC. An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacology 2008 Nov; 55 (6): 1015-22
77. Woolley ML, Marsden CA, Fone KC. 5-ht6 receptors. Curr Drug Targets CNS Neurol Disord 2004 Feb; 3 (1): 59-79
78. West PJ, Marcy VR, Marino MJ, et al. Activation of the 5-HT(6) receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience 2009 Dec 1; 164 (2): 692-701
79. Hirst WD, Abrahamsen B, Blaney FE, et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol 2003 Dec; 64 (6): 1295-308 (Pubitemid 37532219)
80. Bonasera SJ, Chu HM, Brennan TJ, et al. A null mutation of the serotonin 6 receptor alters acute responses to ethanol. Neuropsychopharmacology 2006 Aug; 31 (8): 1801-13 (Pubitemid 44106712)
81. Svenningsson P, Tzavara ET, Qi H, et al. Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation. J Neurosci 2007 Apr 11; 27 (15): 4201-9 (Pubitemid 46597167)
82. Woolley ML, Marsden CA, Sleight AJ, et al. Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790. Psychopharmacology (Berl) 2003 Dec; 170 (4): 358-67 (Pubitemid 38010507)
83. Woolley ML, Bentley JC, Sleight AJ, et al. A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 2001 Aug; 41 (2): 210-9 (Pubitemid 32728092)
84. Hirst WD, Stean TO, Rogers DC, et al. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol 2006 Dec 28; 553 (1-3): 109-19 (Pubitemid 44779592)
85. Perez-Garcia G, Meneses A. Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task. Pharmacol Biochem Behav 2005 Jul; 81 (3): 673-82 (Pubitemid 40966815)
86. Foley AG, Murphy KJ, Hirst WD, et al. The 5-HT(6) receptor antagonist SB-271046 reverses scopolaminedisrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology 2004 Jan; 29 (1): 93-100 (Pubitemid 38068018)
87. Riemer C, Borroni E, Levet-Trafit B, et al. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem 2003 Mar 27; 46 (7): 1273-6 (Pubitemid 36428233)
88. Gerard C, Martres MP, Lefevre K, et al. Immunolocalization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res 1997 Jan 23; 746 (1-2): 207-19 (Pubitemid 27060349)
89. Upton N, Chuang TT, Hunter AJ, et al. 5-HT6 receptor antagonists as novel cognitive enhancing agents forAlzheimer's disease. Neurotherapeutics 2008 Jul; 5 (3): 458-69 (Pubitemid 351952494)
90. King MV, Sleight AJ, Woolley ML, et al. 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation: an effect sensitive to NMDA receptor antagonism. Neuropharmacology 2004 Aug; 47 (2): 195-204 (Pubitemid 38824643)
91. Schechter LE, Lin Q, Smith DL, et al. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 2008 May; 33 (6): 1323-35 (Pubitemid 351521711)
92. Foley AG, Hirst WD, Gallagher HC, et al. The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats. Neuropharmacology 2008 Jun; 54 (8): 1166-74
93. Fiorino F, Severino B, De Angelis F, et al. New 5-HT(1A) receptor ligands containing a N0-cyanoisonicotinamidine nucleus: synthesis and in vitro pharmacological evaluation. Bioorg Med Chem Lett 2010 May 1; 20 (9): 2978-82
94. Flynn DL, Zabrowski DL, Becker DP, et al. SC-53116: the first selective agonist at the newly identified serotonin 5-HT4 receptor subtype. JMed Chem 1992 Apr 17; 35 (8): 1486-9
95. Buchheit KH, Gamse R, Giger R, et al. The serotonin 5-HT4 receptor: 1. Design of a new class of agonists and receptor map of the agonist recognition site. JMed Chem 1995 Jun 23; 38 (13): 2326-30
96. Buchheit KH, Gamse R, Giger R, et al. The serotonin 5-HT4 receptor: 2. Structure-activity studies of the indole carbazimidamide class of agonists. JMed Chem 1995 Jun 23; 38 (13): 2331-8
97. Yang D, Soulier JL, Sicsic S, et al. New esters of 4-amino-5-chloro-2- methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors. J Med Chem 1997 Feb 14; 40 (4): 608-21 (Pubitemid 27080041)
98. Iskander MN, Leung LM, Buley T, et al. Optimization of a pharmacophore model for 5-HT4 agonists using CoMFA and receptor based alignment. Eur JMed Chem 2006 Jan; 41 (1): 16-26 (Pubitemid 43276055)
99. Russo O, BerthouzeM, Giner M, et al. Synthesis of specific bivalent probes that functionally interact with 5-HT(4) receptor dimers. JMed Chem 2007 Sep 6; 50 (18): 4482-92 (Pubitemid 47378844)
100. Russo O, Cachard-Chastel M, Riviere C, et al. Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease. J Med Chem 2009 Apr 23; 52 (8): 2214-25
101. Glennon RA. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem 2003 Jul 3; 46 (14): 2795-812
102. Singer JM, Wilson MW, Johnson PD, et al. Synthesis and SAR of tolylamine 5-HT6 antagonists. Bioorg Med Chem Lett 2009 May 1; 19 (9): 2409-12
103. Ivachtchenko AV, Frolov EB, Mitkin OD, et al. Synthesis and biological activity of 5-styryl and 5-phenethylsubstituted 2,3,4,5-tetrahydro-1H-pyrido[4, 3-b]indoles. Bioorg Med Chem Lett 2010 Jan 1; 20 (1): 78-82
104. Pieper AA, Xie S, Capota E, et al. Discovery of a proneurogenic, neuroprotective chemical. Cell 2010 Jul 9; 142 (1): 39-51
105. Gao M, Wang M, Hutchins GD, et al. [(11)C]Dimebon, radiosynthesis and lipophilicity of a new potential PET agent for imaging of Alzheimer's disease and Huntington's disease. BioorgMed Chem Lett 2010 Apr 15; 20 (8): 2529-32
106. Nirogi RVS, Kothmirkar P, Kambhampati R, et al. Novel and potent 5-piperazinyl methyl-N1-aryl sulfonyl indole derivatives as 5-HT6 receptor ligands [letter]. ACS Med Chem Lett 2010; 1 (7): 340-4
107. Liu KG, Lo JR, Comery TA, et al. 1-Sulfonylindazoles as potent and selective 5-HT6 ligands. Bioorg Med Chem Lett 2009 May 1; 19 (9): 2413-5
108. Pullagurla MR, Westkaemper RB, Glennon RA. Possible differences in modes of agonist and antagonist binding at human 5-HT6 receptors. BioorgMed Chem Lett 2004 Sep 6; 14 (17): 4569-73 (Pubitemid 39043987)
109. de la Fuente T, Martin-Fontecha M, Sallander J, et al. Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists: molecular mechanisms of receptor inactivation. J Med Chem 2010 Feb 11; 53 (3): 1357-69
110. Lopez-Rodriguez ML, Benhamu B, de la Fuente T, et al. A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. J Med Chem 2005 Jun 30; 48 (13): 4216-9 (Pubitemid 40884923)